Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin. by Nath, Kavindra et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Radiation Oncology Faculty Papers Department of Radiation Oncology
12-1-2018
Effect of Differences in Metabolic Activity of
Melanoma Models on Response to Lonidamine
plus Doxorubicin.
Kavindra Nath
University of Pennsylvania
Jeffrey Roman
University of Pennsylvania
David S. Nelson
University of Pennsylvania
Lili Guo
University of Pennsylvania
Seung-Cheol Lee
University of Pennsylvania
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/radoncfp
Part of the Oncology Commons, and the Radiology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Recommended Citation
Nath, Kavindra; Roman, Jeffrey; Nelson, David S.; Guo, Lili; Lee, Seung-Cheol; Orlovskiy, Stepan;
Muriuki, Kevin; Heitjan, Daniel F.; Pickup, Stephen; Leeper, Dennis B.; Blair, Ian A.; Putt, Mary E.;
and Glickson, Jerry D., "Effect of Differences in Metabolic Activity of Melanoma Models on
Response to Lonidamine plus Doxorubicin." (2018). Department of Radiation Oncology Faculty
Papers. Paper 108.
https://jdc.jefferson.edu/radoncfp/108
Authors
Kavindra Nath, Jeffrey Roman, David S. Nelson, Lili Guo, Seung-Cheol Lee, Stepan Orlovskiy, Kevin Muriuki,
Daniel F. Heitjan, Stephen Pickup, Dennis B. Leeper, Ian A. Blair, Mary E. Putt, and Jerry D. Glickson
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/radoncfp/108
1SCiENTifiC REPORts |  (2018) 8:14654  | DOI:10.1038/s41598-018-33019-4
www.nature.com/scientificreports
Effect of Differences in Metabolic 
Activity of Melanoma Models on 
Response to Lonidamine plus 
Doxorubicin
Kavindra Nath1, Jeffrey Roman1, David S. Nelson1, Lili Guo2, Seung-Cheol Lee1, 
Stepan Orlovskiy1, Kevin Muriuki1, Daniel F. Heitjan4,5, Stephen Pickup1, Dennis B. Leeper6, 
Ian A. Blair2, Mary E. Putt3 & Jerry D. Glickson1
Lonidamine (LND), a metabolic modulator, sensitizes DB-1 human melanoma to doxorubicin (DOX) 
chemotherapy by acidifying and de-energizing the tumor. This report compares the effects of LND 
on two human melanoma lines, DB-1 and WM983B, which exhibit different metabolic properties. 
Using liquid chromatography mass spectrometry and Seahorse analysis, we show that DB-1 was more 
glycolytic than WM983B in vitro. 31P magnetic resonance spectroscopy (MRS) indicates that LND 
(100 mg/kg, i.p.) induces similar selective acidification and de-energization of WM983B xenografts 
in immunosuppressed mice. Over three hours, intracellular pH (pHi) of WM983B decreased from 
6.91 ± 0.03 to 6.59 ± 0.10 (p = 0.03), whereas extracellular pH (pHe) of this tumor changed from 
7.03 ± 0.05 to 6.89 ± 0.06 (p = 0.19). A decline in bioenergetics (β-NTP/Pi) of 55 ± 5.0% (p = 0.03) 
accompanied the decline in pHi of WM983B. Using 1H MRS with a selective multiquantum pulse 
sequence and Hadamard localization, we show that LND induced a significant increase in tumor lactate 
levels (p < 0.01). LND pre-treatment followed by DOX (10 mg/kg, i.v.) produced a growth delay of 13.7 
days in WM983B (p < 0.01 versus control), a growth delay significantly smaller than the 25.4 days that 
occurred with DB-1 (p = 0.03 versus WM983B). Differences in relative levels of glycolysis may produce 
differential therapeutic responses of DB-1 and WM983B melanomas.
Metastatic melanoma remains a deadly disease with relatively limited and ineffective treatment options. 
Despite advances in treatment with targeted therapies and checkpoint inhibitors, this disease annually claims 
approximately 10,000 lives in the US1. Targeted therapies exploit common mutations in melanoma such as the 
BRAF-V600E mutation1, but produce only a transient response with median progression-free-survival of 12.3 
months2,3. On the other hand, checkpoint inhibitors such as anti-PD-1(pembrolizumab) and ipilumimab pro-
duce durable responses (over 3 years), but in only ~40% of metastatic melanomas4–7. This observation suggests 
that immunotherapy may have a differential impact depending on the genetic variant of melanoma. There is an 
additional need for better understanding of how various therapies can be targeted toward different variants of 
metastatic disease.
In general, cancer cell lines are known to vary substantially in their metabolic characterstics8. In particular 
cancer tends to prefer glycolytic metabolism even in the presence of oxygen (Warburg effect), although this phe-
notype varies greatly among cancer types. Lonidamine (LND), first introduced in 1979 as an antispermatogenic 
agent9 has limited antineoplastic activity as a single agent but has demonstrated potential in modulating the activ-
ities of conventional cancer therapeutic agents. Our recent studies10 have shown that LND potently inhibits the 
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mitochondrial pyruvate carrier (MPC) activity in isolated rat liver mitochondria (Ki 2.5 μM) and cooperatively 
inhibits L-lactate transport by MCT1, MCT2 and MCT4 expressed in Xenopus laevis oocytes with K0.5 and Hill 
Coefficient values of 36–40 μM and 1.65–1.85, respectively. LND inhibits the succinate-ubiquinone reductase 
activity of respiratory complex II without fully blocking succinate dehydrogenase activity. LND also induces 
cellular reactive oxygen species through complex II, and has been reported to promote cell death by suppression 
of the pentose phosphate pathway, which resulted in inhibition of NADPH and glutathione generation. We con-
cluded that MPC inhibition is the most sensitive anti-tumor target for LND, with additional inhibitory effects on 
MCT-mediated L-lactic acid efflux, complex II and glutamine/glutamate oxidation11. Metabolically, LND inhibits 
respiration11, export of lactic acid11,12, and production of ATP11–14. Together these metabolic effects acidify11–14 
and de-energize11–14 the affected cells. Perhaps because cancer cells are more dependent on glycolysis and normal 
tissue is more dependent on respiration, LND selectively perturbs tumor cells with minimal effects on tissues 
such as liver, muscle or brain12,15. LND has chemotherapeutic12–17 activity as well as the ability to sensitize tumors 
to hyperthermia18–22 and radiation23,24. Clinical trials have evaluated LND’s toxicity and efficacy against several 
malignancies25–27 and benign prostate hyperplasia28.
Recently, we showed that LND selectively acidifies, de-energizes, and sensitizes DB-1 melanoma to doxoru-
bicin (DOX) chemotherapy14. During a three hour experiment on DB-1 xenografts in nude mice treated with 
LND (100 mg/kg, i.p.), the intracellular pH (pHi) fell from 6.90 to 6.33 while the extracellular pH (pHe) was more 
stable dropping only from 7.0 to 6.8012. Simultaneously, the β-NTP/Pi ratio (beta-nucleoside triphosphate/ inor-
ganic phosphate molar ratio (which measures the bioenergetic state of the tumor), as measured by 31P magnetic 
resonance spectroscopy (MRS) decreased monotonically by 67% over a three hour period. In addition, LND pre-
treatment potentiated the antitumor activity of DOX (10 mg/kg, i.v.). Compared to control, DOX alone yielded a 
growth delay of 5.4 days while DOX combined with LND yielded a growth delay of 28.6 days12. This combination 
of LND and DOX produced 98% cell kill with one dose14.
Our earlier study raised questions about whether the dramatic enhancement of the response of DB-1 to DOX14 
was consistent across different melanoma cell lines, or whether there were specific metabolic characteristics of 
the DB-1 line that made it particularly susceptible to treatment with LND. In the current study, we contrast the 
response of DB-1 to the WM983B human melanoma model. WM983B is an established human melanoma cell 
line and xenograft model that, like DB-1 expresses BRAF-V600E, a characteristic mutation in melanoma which 
is selectively targeted by the BRAF kinase inhibitor vemurafenib16. We evaluated the metabolic and therapeutic 
effects of LND on WM983B both in vitro and in vivo. We also considered any differential responses to LND 
between WM983B and DB-1 cells and xenografts and used our understanding of the mechanism of action of 
LND action to interpret these differential responses. This study adds to our understanding of improvements to 
cancer therapy in two ways. First we are able to assess the metabolic response to a chemotherapy modulator in 
vivo using a unique non-invasive MR technique. Secondly, our work provides insight on the mechanistic basis 
for differences in the effect of this metabolic modulator on response to chemotherapy of the two melanoma lines.
Results
Liquid Chromatography Mass Spectrometry (LC-MS) Metabolite Quantification in Cells. LND 
induces different metabolic responses in DB-1 and WM983B melanoma cell lines. In particular, increases in lac-
tate were noticeably higher in DB-1 while increases in glutamate and  α-ketoglutarate were noticeably higher in 
WM983B (Fig. 1). Aspartate, oxaloacetate, G3P/DHAP and G6P/F6P declined sharply in WM983B in contrast to 
DB-1 where these metabolites exhibited only small changes.
Seahorse and YSI Cell Metabolism Assays. DB-1 is a more glycolytic melanoma cell line than WM983B. 
DB-1 has significantly higher basal extracellular acidification rate (ECAR) (p < 0.001) and lower oxygen con-
sumption rate to extracellular acidification rate ratio (OCR)/ECAR ratio (p < 0.001) (Table 1, Fig. 2).
LND induces decreases in metabolic rates in both DB-1 and WM983B. LND induces ECAR inhibition in 
both DB-1 and WM983B within the first hour of treatment (Fig. 2a,b). Figure 3 shows the minimum value of 
ECAR as a function of LND dose. The acute response of ECAR to LND is concentration-dependent with con-
siderable inhibition occurring at doses of 100 µM and greater (Fig. 3). DB-1 consistently exhibited larger mean 
values of ECARmin (p < 0.001). There was no evidence of modification of these differences by LND concentration 
(p = 0.58). LND induces inhibition of both OCR and ECAR over a threehour period post-treatment, with greater 
doses inducing greater reductions (Fig. 2a–d). The LND inhibition of metabolic rates persists after stressing the 
cells with oligomycin and carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) then rotenone (Rot) 
with antimycin A (AA) (Fig. 2e–f).
Magnetic Resonance Spectroscopy of Melanoma Xenografts in Mice. For WM983B xenografts, 
exposure to LND decreased the bioenergetic status and selectively acidified the tumor. We show representative 
localized 31P MR spectra before and after LND treatment in WM983B (Fig. 4a) and DB-1 melanoma xenografts 
(Fig. 4b). Of note, LND caused a decrease in β-NTP with a simultaneous increase in Pi. The β-NTP/Pi remained 
low at 55 ± 0.05% of the baseline level for up to 120 min (differences from baseline were statistically significant 
(p < 0.05) at t = 100, 120, 160) in WM983B melanoma xenografts. The integrated intensity of β-NTP and Pi max-
imum decreased by 28% and increased by 68%, respectively, after LND administration.
After LND treatment, the tumor pHi of WM983B xenografts decreased from 6.91 ± 0.03 to 6.59 ± 0.05 
(p < 0.01 for all times except t = 180 min), reaching its lowest point at 100 minutes post- treatment (Fig. 5). In 
contrast, the tumor pHe of this tumor declined only slightly, from 7.03 ± 0.05 to 6.89 ± 0.06 (difference in pHe 
not statistically significant at any time point) (Fig. 5). Simultaneously, lactate concentrations were significantly 
elevated (p < 0.01) at 40 min after LND administration (Fig. 5). Since the pHi decreased more than pHe, and since 
extracellular volume fraction is ~40% in experimental tumors29,30, we conclude that most of the lactate increase 
www.nature.com/scientificreports/
3SCiENTifiC REPORts |  (2018) 8:14654  | DOI:10.1038/s41598-018-33019-4
was primarily intracellular. 3-aminopropylphosphonate (3-APP) (control sham) did not change tumor pHi, pHe, 
or lactate levels over a three hour period (data not shown).
Tumor Growth Delay Studies with Doxorubicin. In the control groups, tumors for the WM983B and 
DB-1 melanoma xenografts doubled at very similar rates (5.52 days for DB-1 and 5.37 days for WM983B). As 
reported earlier for DB-1, LND provides a dramatic potentiation of DOX toxicity. Notably, in DB-1 DOX admin-
istered alone induced a growth delay of 8.1 (90% CI 21.0, 29.1) days compared to control, whereas LND + DOX 
induced a growth delay of 25.4 (90% CI 6.1, 10.2) days versus control (Fig. 6, Table 2). Compared to control, 
percent survival of WM983B was 36.2% (90% CI 27.2, 47.2) for DOX alone and 4.1% (90% CI 2.5, 7.4) for 
DOX + LND. WM983B was also potentiated by LND but not to the same extent as DB-1. For WM983B, no signif-
icant growth delay was noted for DOX alone (p = 0.20, 90% CI −2.3, 11.1) whereas with LND + DOX, a growth 
delay of 13.7 days was observed (90% CI 7.6, 20.3, p = 0.005) (Fig. 6, Table 2). Compared to control, percent 
survival in WM983B was also not significantly reduced (p = 0.15, 90% CI, 15.4, 126.4) with DOX alone but fell to 
17.1% (90% CI 3.5, 45.9 p < 0.001) with LND + DOX (Fig. 6, Table 2). For tumors treated with a combination of 
LND + DOX, the mean growth delay for DB-1 of 25.4 days was significantly longer than for WM983B (p = 0.032). 
No other differences between the cell lines achieved statistical significance (Fig. 6, Table 2).
LND produced minor systemic toxicity to our mice with WM983B tumors. Mice that received LND alone lost 
2.4% of their body weight by day 1 and returned to baseline by the next day. Mice that received DOX alone lost 
13% of their body weight within 11 days of injection and then showed no further weight loss for at least 40 days. 
Mice that received both LND and DOX experienced similar weight loss to mice that received DOX alone (data 
not shown).
Figure 1. Lonidamine (LND) induces different metabolic responses in WM983B and DB-1 human melanoma 
cells one hour post treatment. For a given metabolite and cell line, we calculate fold change as the intracellular 
metabolite amount in the LND group divided by the mean metabolite amount in the CTRL (DMSO sham) 
group. These fold changes are represented as log base 2. Data shown as mean ± SD.
Metabolic Parameter
WM983B DB-1
p-valuemean ± S.D. n mean ± S.D. n
Basal OCR1 90 ± 10 23 94 ± 5 23 <0.001
Stressed OCR1 200 ± 20 3 200 ± 10 3 0.989
Basal ECAR2 24 ± 2 23 38 ± 2 23 <0.001
Stressed ECAR2 61 ± 3 3 74 ± 5 3 0.056
Basal OCR/ECAR Ratio3 3.5 ± 0.3 23 2.5 ± 0.2 23 <0.001
Glucose Consumption4 4 ± 2 16 7 ± 3 11 0.003
Lactate Production4 7 ± 3 16 14 ± 5 11 0.003
Table 1. WM983B cells are less glycolytic than DB-1 cells. We display metabolic parameters derived from 
in vitro Seahorse and YSI metabolic assays, including oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR). Data shown as mean ± S.D. 1pmol/2 × 104 cells/min; 2mpH/2 × 104 cells/min; 3pmol 
O2/mpH; 4nmol/106 cells/min.
www.nature.com/scientificreports/
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Discussion
DB-1 and WM983B human melanoma xenografts appear to respond similarly to LND, although the response was 
somewhat muted in WM983B. LND selectively acidified WM983B tumors causing a noticeable decrease in pHi 
and a minimal drop in pHe. Simultaneously, LND de-energized WM983B tumors, causing a decrease in β-NTP 
and an increase in inorganic phosphate. In addition, LND pre-treatment potentiated single-dose DOX to produce 
cell kill that was significantly greater than that of DOX alone. Compared to DB-1 melanoma xenografts, WM983B 
displayed less acidification, de-energization, and potentiation in chemotherapy response. These two cell models 
were chosen based on the diverse nature of their metabolomics, but with similar oncogenic phenotypes both 
carrying the V600E BRAF mutation.
Figure 2. Lonidamine (LND) induces a concentration-dependent decrease in metabolic rates in WM983B 
and DB-1 human melanoma cells. For WM983B and DB-1, respectively, (a,b) show extracellular acidification 
rate (ECAR) vs. time after LND treatment. (c,d) show oxygen consumption rate (OCR) vs. time after LND 
treatment. (e,f) show OCR vs. time after LND treatment upon addition of oligomycin (Oligo) with carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), then rotenone (Rot) with antimycin A (AA). Data 
shown as mean ± s.e.m.
www.nature.com/scientificreports/
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LND-induced acidification likely contributes to DOX sensitization by inhibiting the MCT and MPC resulting 
in tumor acidification. LND may cause free alkaline DOX (pKa~8.5) to be more readily retained in the acidified 
tumor cells (cation trapping)14. Since WM983B melanoma xenografts are less glycolytic and less acidified by LND 
than DB-1 melanoma xenografts, they may experience less cation trapping and thus less response to DOX31.
Interestingly, WM983B melanoma xenografts seem to upregulate glutaminolysis after LND treatment, to 
compensate for the energy loss associated with blocking MPC. We determined that glutaminolysis was being 
employed for anaplerotic flux into the TCA cycle based on the LC-MS data (Fig. 1) showing increases in interme-
diary metabolites immediately downstream of glutamine, specifically glutamate and α-ketoglutarate. This effect 
was specific to WM983B, which is the less bioenergetically affected of the two melanoma cell lines, so we believe 
that this anaplerotic flux plays a role in its diminished response. Glutamine is required for proliferating tumor 
cells as it participates in bioenergetics, supports cell defenses against oxidative stress and complements glucose 
metabolism in the production of macromolecules32. This metabolic pathway may be the escape mechanism used 
by WM983B melanoma xenografts and should be studied further.
By trapping lactate inside tumor cells, we wanted to exploit this natural preference of tumors for glycolytic 
metabolism. Glycolysis selectively induces intracellular acidification of the tumor through accumulation of lactic 
acid even under aerobic conditions. This selective tumor acidification and de-energization (caused by inhibition 
of pyruvate uptake by mitochondria and by inhibition of complex II) can greatly enhance tumor response to 
chemotherapeutic agents such as N-mustards and DOX12–17. Others have shown that LND sensitizes tumors to 
hyperthermia18,20–22, radiotherapy23,24 and photodynamic therapy33 by a variety of different mechanisms. Through 
cation trapping, LND may enhance the uptake and retention of various other cancer drugs including anthracy-
clines, which are weakly basic. Swietach et al. have shown the importance of pHi in determining the uptake and 
efficacy of DOX on the basis of pH-partitioning across cell-surface and pH-sensitivity of binding to nuclear sites 
which maintains DOX in a slowly-releasable form34. Our study demonstrates that reversal of the pH gradient 
caused by LND should increase uptake of weak bases such as DOX by melanoma cells. There is no reason to 
believe that the acidification and reversal of the pH gradient seen with these melanoma cell lines would not occur 
with other tumor types. By taking advantage of the altered physiological phenotype of the tumor, the addition of 
LND to traditional chemotherapy modalities could result in improved therapeutic gain.
Figure 3. Lonidamine (LND) induces a concentration-dependent acute inhibition of extracellular acidification 
in DB-1 and WM983B human melanoma cells. We show ECARmin the lowest measured extracellular 
acidification rate within the first 60 minutes of LND treatment, against LND concentration (in µM). ECARmin 
for DB-1 was significantly larger than for WM983B (p < 0.001 F1,34 = 145) and there were significant effects as 
well for LND concentration (p < 0.001, F5,34 = 9.2). Dotted lines connect LND concentrations of either 0, 1 or 
10 uM with higher concentrations where there were significantly different mean levels of ECARmin. (adjusted 
p < 0.001 ***p < 0.001**p < 0.05*) e.g. mean ECARmin differed significantly between 0 & both 150 and 200 uM 
LND (p < 0.05).
www.nature.com/scientificreports/
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LND-induced acidification also inhibits key DNA-repair enzymes such as O6-alkylguanine DNA alkyltrans-
ferase, so LND can also potentiate therapies such as temozolomide treatment that damage the DNA of cancer 
cells17. In addition, by inhibiting tumor respiration, LND may increase tumor oxygenation and thus increase the 
effect of reactive oxygen species that play an important role in the activity of some anti-cancer agents most nota-
bly radiation therapy that have a free-radical intermediate in their action. We found that while LND alone and 
DOX alone had minimal effects on melanoma growth the combination of these agents administered according 
to a schedule based on MRS measurement of tumor pHi, substantially decreased the growth rate of this highly 
malignant tumor. This could provide a method for improved systemic therapy of this deadly cancer.
LND-induced de-energization may also contribute to DOX sensitization. Multi-drug resistance appears to 
be mediated by an energy dependent mechanism whereby a p-glycoprotein pumps cytotoxic drugs out of the 
tumor14,34. By blocking the MPC and de-energizing tumor cells, LND may reduce tumor ATP levels and thereby 
reduce multi-drug resistance. Because WM983B cells are inherently less energetic than DB-1 cells in vitro, we 
predict that LND should induce less de-energization in WM983B xenografts and thus be less effective in potenti-
ating the toxic effects of DOX. This is indeed what we observed. At least conceptually, this model has potential for 
translation to clinical settings. Notably, we now have instruments and methodologies to non-invasively monitor 
tumor metabolism and energetics. Bioenergetic measurements could form the basis of predictions about the 
response of the tumor to an energetically demanding treatment. Melanoma therapy has been recently directed 
toward immunotherapy and specific BRAF V600E inhibitors. Although these novel targeted therapies are prom-
ising, curative systemic treatment of melanoma remains elusive for the majority of melanoma patients. It is rea-
sonable to think that information about metabolism could also be highly useful in monitoring and predicting 
response to other treatment modalities such as BRAF inhibitors and immunotherapy.
Materials and Methods
Reagents. DMEM, glutamine, HEPES, penicillin-streptomycin, trypsin-EDTA, DPBS, sodium pyruvate, and 
HBSS were purchased from Thermo Fisher Scientific (Waltham, MA, USA; Invitrogen brand). FBS was pur-
chased from HyClone Laboratories, Inc. (Logan, UT, USA). Glucose, DMSO, methanol, water, phenylhydrazine 
hydrochloride, trizma base, and glycine were purchased from Sigma-Aldrich (St. Louis, MO, USA). T-75 flasks, 
trypan blue, and 10-cm culture dishes were purchased from Corning Life Sciences (Tewksbury, MA, USA; Falcon 
Figure 4. Lonidamine (LND) causes a decrease in bioenergetics in WM983B xenografts. We show 
representative in vivo localized (Image Selected In vivo Spectroscopy; ISIS) Phosphorus-31 magnetic resonance 
spectroscopy (31P MRS) spectra of (a) WM983B and (b) DB-1 xenografts43. In each set, the lower spectrum 
represents the baseline and upper represents 180 minutes post-LND treatment. We mark resonances for 
3-aminopropylphosphonate (3-APP), phosphomonoesters (PME), inorganic phosphate (Pi), γ-nucleoside-
triphosphate (γ-NTP), α-nucleoside-triphosphate (α-NTP), and β-nucleoside-triphosphate (β-NTP). A 
decrease in β-NTP levels with corresponding increase in Pi indicates impaired energy metabolism.
www.nature.com/scientificreports/
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brand). LND and 3-APP were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Seahorse 
XF Base Medium, oligomycin, FCCP, rotenone, and antimycin A were purchased from Seahorse Bioscience, Inc. 
(North Billerica, MA, USA). DOX was purchased from Midwest Veterinary Supply (Burnsville, MN, USA).
Male athymic nude mice (01B74) 4–6 weeks of age were purchased from the National Cancer Institute 
(Frederick, MD, USA) and housed in microisolator cages with access to water and autoclaved mouse chow ad 
libitum. For in vivo experiments, the following accessories were purchased from the following vendors: a respi-
ration pillow from SA Instruments Inc. (Stony Brook, NY, USA; Model 1025), water pad heater from Gaymar 
Industries, Inc. (Orchard Park, NJ, USA), catheters from Tyco Healthcare (Milwaukee, WI, USA), restrainer from 
Braintree Scientific, Inc. (Braintree, MA, USA), calipers from Bel-Art Products (Wayne, NJ, USA), and scale from 
H&C Weighing Systems (Columbia, MD, USA; Acculab PP401).
Cell Culture. Our culture medium for WM983B cells consists of DMEM supplemented with 10% FBS, 
25 mM glucose, 4 mM glutamine, 10 mM HEPES, 100 units/mL penicillin, and 100 µg/mL streptomycin. We grew 
WM983B cells in T-75 flasks with this culture medium and incubated the cells at 37 °C and 5% CO2. We passaged 
the cells at 80% confluence using 0.05% trypsin-EDTA for 2 minutes, and split the cells 1/20 into new flasks. For 
experiments requiring specific cell numbers, we counted the cell suspensions with a hemocytometer using trypan 
blue stain. We cultured DB-1 cells as described previously12,14–17.
Figure 5. Lonidamine (LND) causes simultaneous acidification and de-energization of WM983B human 
melanoma xenografts. For comparison, we include previously published results for DB-1 xenografts12 
Intracellular pH (pHi) differed by melanoma line (p = 0.036, F1,20) while no differences between cell lines 
were detected for pHe. Bioenergetics (ratio of β-nucleoside triphosphate to inorganic phosphate (β-NTP/Pi) 
differed by tumor line (p = 0.029, F1,20) while lactate showed differential effects by  tumor as a function of time 
(p = 0.008, F1,48) (d) shows tumor lactate relative to baseline (n = 5). Data shown as mean ± s.e.m.
www.nature.com/scientificreports/
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LC-MS Metabolite Quantification. DB-1 or WM983B cells were grown in 10-cm culture dishes until 
reaching 80% confluency. Medium was replaced with fresh culture medium containing LND (150 µM) or DMSO 
vehicle (0.15%) and cells incubated for one hour. Next, cells were washed three times with cold DPBS and scraped 
Figure 6. Lonidamine (LND) sensitizes both DB-1 and WM983B human melanoma xenografts to doxorubicin 
(DOX). On Day 0, nude mice with WM983B xenografts received treatment as follows: Control (sham i.p. tris/
glycine + sham i.v. PBS), LND (100 mg/kg i.p.), DOX (10 mg/kg i.v.), LND + DOX). The plots show the growth 
measurements for each animal relative to tumor volume at Day 0. Dark lines are the Loess-smoothed curves 
for each treatment group. The dashed line at 2 indicates 4 doublings. The data in the controls up to 12 days were 
used to determine doubling time. The data for DB-1 were re-analyzed from a previous publication in order to be 
comparable to the analysis for WM983B14.
Treatment Group 
(versus Control)
Growth Delay (days)*
(Mean with 90% CI)
Surviving Fraction (%)*
(Estimate with 90% CI)
Number of 
Animals (n)
DB-1 WM983B p** DB-1 WM983B p** DB-1 WM983B
Lonidamine (LND) 4.4(1.5, 7.4)
7.9
(0.1, 16.8) —
57.8
(38.8, 83.2)
36.0
(6.1, 99.2) — 4 5
p-value* 0.047 0.108 0.55 0.026 0.053 0.82
Doxorubicin (DOX) 8.1(6.1, 10.2)
3.7
(−2.3, 11.1) —
36.2
(27.2, 47.2)
62.1
(15.4, 126.4) — 5 5
p-value* <0.001 0.201 0.34 <0.001 0.153 0.79
LND + DOX 25.4(21.0, 29.1)
13.7
(7.6, 20.3) —
4.1
(2.5, 7.4)
17.1
(3.5, 45.9) — 5 8
p-value* < 0.001 0.005 0.032 < 0.001 < 0.001 0.90
Table 2. Lonidamine (LND) induces a lesser potentiation to doxorubicin (DOX) in WM983B human 
melanoma xenografts compared to DB-1 human melanoma xenografts. We show estimated growth delay (T-
C), doubling time (Td), and surviving fraction as percent by treatment arm in WM983B and DB-1 xenografts 
following LND administration. The data for DB-1 were re-analyzed from a previous publication in order to 
be comparable to the analysis for WM983B14. In the control, doubling times were 5.52 days for DB-1 and 5.38 
days for WM983B. *p-value for one-sided test comparing each treatment group to control **Two-sided p-value 
comparing the two cell lines.
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with 750 µL methanol: water (80:20) containing 1 mg phenylhydrazine hydrochloride and pulse-sonicated for 
20 seconds. Extracts were centrifuged at 17,000 × g and supernatants retained. Supernatants were dried with 
nitrogen gas and resuspended in mobile phase for LC-MS analysis.
Seahorse and YSI Metabolic Assays. In vitro oxygen consumption and extracellular acidification rates 
were measured with the Seahorse XFe96 Analyzer. For our custom protocol, 2 × 104 cells were seeded per well and 
assay medium was made by supplementing Seahorse XF Base Medium with 5 mM glucose, 2 mM L-glutamine, 
and 1 mM sodium pyruvate. First three basal OCR and ECAR measurements (3-0-3 mix-wait-measure cycle) 
were performed. Next, LND (0, 1, 10, 100, or 150 µM; 0.2% DMSO) was injected and measurements were made 
for three hours. Then, 1 µM FCCP and 1 µM oligomycin were added, and three measurements were made. Lastly, 
0.5 µM rotenone and 0.5 µM antimycin A were added followed by three measurements. After this experiment, 
cells were typsinized with 0.05% trypsin-EDTA and counted with a hemocytometer. Simultaneously, glucose and 
lactate concentrations in the medium were measured using a YSI 2300 STAT Plus Glucose & Lactate Analyzer 
calibrated with YSI 2747 dual standard. To calculate the glucose consumption and lactate production rates, we 
assumed that the cells were in the logarithmic growth phase and that the change in the amounts of metabolites 
was proportional to the number of cells in the flask. Under these assumptions, glucose consumption and lactate 
production rates were calculated with the following equation,
=
−
−

( )
A
(A(t) A(0))ln
t(N(t) N(0)) (1)
N(t)
N(0)
where N(t) is the number of cells at time t after seeding, N(0) is the number of cells seeded, A(t) is the amount of 
a given metabolite in the well at time t, and A is the characteristic metabolic rate. Note that if A is positive, the 
metabolite is net-produced; if A is negative, A is net-consumed.
Human Melanoma Xenografts in Nude Mice and in vivo Doubling Time Calculation. WM983B 
xenografts were grown in nude mice as described in our previous publications with DB-1 melanoma xeno-
grafts12,14–17,35. Briefly, 1 × 106 cells in 100 µL HBSS were inoculated subcutaneously in the right flank of nude 
mouse. In vivo xenograft doubling times were calculated by measuring tumor growth in untreated mice with 
calipers, using the formula for the volume of a half-ellipsoid, V = (π/6) (l × w × d), where l is the tumor’s length, 
w is the tumor’s width, and d is the tumor’s depth. Tumor doubling times were calculated from the slopes of 
the log-linear portion of the tumor growth curves (determined by linear regression analysis) using the formula 
td = 0.3010 /m, where m is the slope.
Magnetic Resonance (MR) Experiment for pH Measurement and Bioenergetics Status 
Estimation. MR experiments were performed on a 9.4 T/31-cm horizontal bore Varian system. Changes in 
pHi and pHe were measured using 31P MRS by positioning the tumor in a dual-frequency (1H/31P) slotted-tube 
resonator (10 mm diameter) built in-house. For 31P MRS, the Image Selected In vivo Spectroscopy (ISIS) tech-
nique was used with the following parameters: Hyperbolic Secant-Adiabatic Fast Passage (HS-AFP) slice-selective 
inversion pulses with 2.5 ms length, 296 scans with a radiofrequency pulse width of 60 µs, corresponding approx-
imately to a 90° flip angle; sweep width, 12 kHz; 512 data points; TR = 4 s.
Lactate was measured using 1H MRS by positioning the tumor in a single frequency (1H) slotted-tube resona-
tor (13 mm inner diameter, 15 mm outer diameter, 16.5 mm depth) built in-house. For 1H MRS, a slice-selective, 
double-frequency, Hadamard-selective, multiple quantum coherence transfer pulse sequence was used to 
detect lactate and to filter out overlapping lipid signals36. Following acquisition parameters were used: sweep 
width = 4 kHz; 2048 data points; TR = 8 s; 128 scans.
Magnet was shimmed globally until the water line-width of the tumor monitored via the 1H channel reached 
60–70 Hz. The point resolved spectroscopy (PRESS) sequence was used to shim the ISIS tumor voxel of 250–
300 mm3 volume covering the entire tumor depending on tumor size to 30–40 Hz line width.
To prepare tumor-bearing mice implanted with WM983B for MR experiments, 1% isoflurane in 1 L/min oxy-
gen was used to anesthetize the mice. To monitor heart rate, respiration, and core temperature, sub-dermal needle 
electrodes, a respiration pillow, and a rectal thermistor were used, respectively. Mouse’s core temperature was 
maintained at 37 ± 1 °C by blowing warmed air into the bore of the magnet with heating controlled by a thermal 
regulator system. After acquiring the baseline MR spectrum, we injected LND (100 mg/kg) or 0.2 mL of a 300 mg/
mL solution of 3-APP (in water; for measurement of pHe)12 through two 26-gauge i.p. catheters inserted into 
either side of the peritoneum without removing the animal from the magnet.
To prepare the LND for injection, a tris/glycine buffer consisting of trizma base (1.2 g) and glycine (5.76 g) in 
sterile water (100 mL; final pH = 8.3) was prepared37. We then dissolved approx. 5 mg LND in tris/glycine buffer 
(to 22.0 mg/mL), and we vortexed the solution at 40 °C until it was clear.
All MR studies were performed on tumors ~250 mm3 in volume and hemispherical in shape. These tumors 
had sufficient size for optimal spectra and fit the available coils. With this tumor size, we could also obtain a spa-
tially localized spectrum to avoid contamination of tumor metabolites with exogenous metabolites from muscle. 
pHi, pHe, lactate, and bioenergetics (β-NTP/Pi) data were analyzed using methods as described previously12,14,15. 
pHi and pHe were determined from the Henderson -Hasselbach (pH = pKa + log[α/(1-α)]) where pKa is the 
dissociation constant of the indicator (Pi or 3-APP, respectively) and α is the degree of ionization of Pi or 3-APP, 
which can be determined from the chemical shift of these pH indicators. 3-APP is a membrane impermeable 
phosphate, which is sensitive to the extracellular pH, whereas Pi is assumed to be completely intracellular. The 
chemical shifts of Pi and 3-APP, were referenced relative to the α-NTP resonance, which is pH insensitive, and 
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the degree of ionization of Pi and 3-APP were measured relative to the limiting chemical shifts determined for 
complete dissociation of Pi or 3-APP), respectively. For pHe, a pKa value of 6.90 ± 0.03, limiting acid chemical 
shift of 34.22 ± 0.04 ppm and base chemical shift of 31.08 ± 0.04 ppm were used, and, for pHi, the corresponding 
parameters were 6.57 ± 0.03, 13.52 ± 0.03 ppm and 11.24 ± 0.02 ppm, respectively30,38–41.
The ratio of the peak areas of β-NTP to Pi resonances represents the ratio of high energy phosphates to low 
energy phosphates, served as an index of the overall bioenergetic status of the tumor. The β-NTP signal is prefer-
ably used to determine the β-NTP/Pi ratio since it is not contaminated with signals from ADP, NAD+ or NADH, 
as is the case for α- and γ-NTP peaks38.
Treatment with Doxorubicin and Growth Delay Measurements. WM983B xenografts were grown 
in nude mice until the tumors reached ~50 mm3. At this point, four cohorts of age- and weight-matched mice 
were assigned to the following treatment groups: Control, LND, DOX, and LND + DOX. The Control group 
(5 mice) received sham treatment with tris/glycine buffer i.p. and then, 40 minutes later, sham treatment with 
PBS i.v. The LND group (5 mice) received 100 mg/kg LND i.p. and then, 40 minutes later, sham PBS i.v. The 
DOX group (5 mice) received sham tris/glycine buffer i.p. and then, 40 minutes later, 10 mg/kg DOX i.v. The 
LND + DOX group (10 mice) received 100 mg/kg LND i.p. and then, 40 minutes later, 10 mg/kg DOX i.v. We 
injected the DOX 40 minutes after the LND injection so that the DOX treatment coincided with the tumor’s max-
imum LND-induced acidification as determined by our MR experiments.
Before all treatment procedures, all mice were anesthetized with 10 mg/mL ketamine hydrochloride and 1 mg/
mL acepromazine, and to maintain sedation we gave additional anesthesia every 45–60 minutes. Heating pads 
were used to maintain body temperature of mice during anesthesia. For the i.v. injections, we restrained the 
mice using a Mouse Tail Illuminator and then applied tail vein catheters filled with 100 USP Units/mL heparin to 
prevent blood clotting. For the first five days post-treatment, tumor dimensions and body weight were measured 
daily with calipers and scale, respectively. After these first five days, these measurements were made every other 
day. Tumor volume was calculated from its dimensions as described above. Animal studies were performed in 
accordance with our protocol under the approval of the University of Pennsylvania Institutional Animal Care and 
Use Committee (IACUC).
Our endpoint for growth delay experiments was four doublings in tumor size (relative to pretreatment vol-
ume). Hence, we performed our experiment on the smallest measurable tumor size (50 mm3) since we did not 
want our tumors to exceed 1000 mm3 in size.
Statistics. Data are described graphically and using summary statistics (means, standard deviation (s.d.) or 
standard error of the mean (s.e.m.). For the experiments to determine whether the minimum value of extracel-
lular acidification differed by cell line and concentration, we used two-way analysis of variance (ANOVA). The 
two factors were LND dose and time. To adjust for multiple comparisons, Tukey Honest significant difference 
intervals were used to determine how ECARmin differed as a function of LND concentration.
For the analysis of the NMR measures where the outcome variable was either lactate, β-NTP/Pi, pHi or pHe, 
we fit a two-way repeated measures ANOVA model to the data to account for the effect of repeated measurements 
of each replicate culture over time. Factors in the ANOVA were cell line and time of observation.
For the analysis of the Seahorse data, basal rates were compared using data from all LND concentrations as 
these rates were collected prior to LND administration. For the analysis of the ‘stressed’ data, we used only data 
without LND. Here two-sample t-tests were used.
To estimate treatment effects on tumor growth, we conducted a growth delay analysis42. For each animal, we 
recorded the time from treatment until the tumor reached a volume of four times the volume at the initiation of 
treatment. We then averaged these times in the treated (T) and control arms (C). For the control animals in each line 
we computed the average slope (B) of the log tumor volume and converted this rate to a doubling time. We estimated 
the proportion of the tumor cells surviving treatment as e−(T−C) × B. We computed 90% confidence intervals by the 
bootstrap percentile method. We compared the DB-1 and WM983B groups using a two-group t-test with standard 
errors computed using bootstrapping. We note that these methods are slightly different from the original analysis 
of the DB-1 line14. Due to policy changes in our animal facility, the tumor volumes prior to Day 0 were larger for 
the DB-1 mice than for the WM983B mice. For WM983B, we judged the volume measurements prior to Day 0 to 
be too noisy to be included in the growth rate analysis. For consistency, we re-analyzed the DB-1 data to ensure that 
the analyses were consistent for both sets of animals. The original and re-analysis yielded similar, but not identical 
results. We conducted these analyses in R, Version 3.4.2 R(Foundation for Statistical Computing)43.
Data Availability
All data are available upon request.
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